Faron Pharmaceuticals Oy

Bexmarilimab (Clevegen) development update

Mon, Mar 22, 2021 08:00 CET

Faron Pharmaceuticals Oy (“Faron” or the “Company”) Bexmarilimab (Clevegen) development update · Significant survival benefit observed in patients responding to bexmarilimab treatment with risk of death reduced by 88% · Gastric cancer becomes sixth tumour cohort to show early signs of clinical efficacy · Data monitoring committee recommends dose escalation expansion in all six cohort types besides ongoing colorectal cancer Company announcement, 22 March 2021 at 9.00 AM (EET)Inside information TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON),

Managers’ transactions

Wed, Jul 08, 2020 16:00 CET

(“Faron” or the “Company”)Company announcement, 8 July 2020 at 5 PM (EEST) TURKU - FINLAND - Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company, announces today that Mr Toni Hänninen, Chief Financial Officer of the Company, acquired 4,400 ordinary shares in Faron at a price of €3.510 per share on 8 July 2020. Following these purchases, Mr Hänninen holds 54,697 ordinary shares in the Company. The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Share

Bexmarilimab (Clevegen) development update

Managers’ transactions

Subscribe